Latest News on CVRX

Financial News Based On Company


Advertisement
Advertisement

CVRX DEADLINE: SueWallSt Reminds CVRx, Inc. Investors of Upcoming Securities Class Action Deadline

https://www.prnewswire.com/news-releases/cvrx-deadline-suewallst-reminds-cvrx-inc-investors-of-upcoming-securities-class-action-deadline-302945524.html
SueWallSt is notifying investors in CVRx, Inc. (Nasdaq: CVRX) of a class action lawsuit filed on behalf of shareholders who purchased securities between July 25, 2023, and August 6, 2026. The lawsuit alleges that CVRx's revenue growth, particularly for its Barostim device, was partly driven by unlawful sales practices involving kickbacks and false claims to government health programs. Shareholders have until January 8, 2027, to apply to serve as lead plaintiff in the case, which was prompted by a U.S. Department of Justice civil investigative demand under the False Claims Act, causing CVRx shares to drop 60%.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in CVRx, Inc. of Class Action Lawsuit and Upcoming Deadlines - CVRX

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-cvrx-inc-of-class-action-lawsuit-and-upcoming-deadlines--cvrx-302944940.html
Pomerantz LLP has filed a class action lawsuit against CVRx, Inc. (NASDAQ: CVRX) on behalf of investors who incurred losses. The lawsuit alleges securities fraud and other unlawful business practices, citing several instances where the company's stock price dropped significantly following negative financial reports, sales force issues, and a Department of Justice investigation. Investors have until January 8, 2027, to seek appointment as Lead Plaintiff in the case.

CVRX: Barostim’s growth push faces specialist staffing and payer-access headwinds

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4703967:0-cvrx-barostim-s-growth-push-faces-specialist-staffing-and-payer-access-headwinds/
CVRX's Barostim device, which targets the heart-failure market, shows promise in improving symptoms based on trial and clinical evidence. However, its growth is currently limited by challenges in sales execution, specialist staffing, and obtaining payer approvals. The company is actively working on expanding coverage and building referral networks to overcome these obstacles.

What Should CVRx, Inc. Investors Know After 59.76% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline

https://www.prnewswire.com/news-releases/what-should-cvrx-inc-investors-know-after-59-76-stock-drop-the-law-offices-of-frank-r-cruz-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302944310.html
The Law Offices of Frank R. Cruz has filed a class action lawsuit against CVRx, Inc. (NASDAQ: CVRX) on behalf of investors who purchased securities between July 25, 2023, and August 6, 2026. The lawsuit alleges that CVRx engaged in illegal and unsustainable sales practices, including improper marketing and kickbacks, which led to a significant stock drop after the U.S. Department of Justice initiated an investigation under the False Claims Act. Investors who suffered losses have until January 8, 2027, to move for lead plaintiff.

CVRx's conference chat is scheduled to stream live at 3 p.m. ET Dec. 2

https://www.stocktitan.net/news/CVRX/cv-rx-to-participate-at-the-piper-sandler-38th-annual-healthcare-utkcsdx9flkc.html
CVRx (NASDAQ: CVRX) announced that its management team will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026, at 3:00 p.m. ET. A live audio webcast of the event will be available on the company's investor relations website. CVRx, a medical device company, focuses on neuromodulation solutions for cardiovascular diseases, with its Barostim™ technology approved for heart failure patients.
Advertisement

CVRX Shareholder Alert: CVRx, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

https://www.prnewswire.com/news-releases/cvrx-shareholder-alert-cvrx-inc-securities-class-action-lawsuit---investors-with-losses-may-contact-levi--korsinsky-302943462.html
Levi & Korsinsky, LLP has filed a class action lawsuit against CVRx, Inc. (Nasdaq: CVRX) on behalf of investors who purchased securities between July 25, 2023, and August 6, 2026. The lawsuit follows a 60% single-session stock decline after CVRx disclosed a federal False Claims Act probe into alleged Barostim kickbacks and issued a guidance cut due to weak sales force productivity. Investors with losses are encouraged to contact the firm by January 8, 2027, to be considered for lead plaintiff.

CVRX INVESTORS Contact Kirby McInerney LLP About the Securities Fraud Lawsuit Filed on Behalf of CVRx, Inc. Shareholders

https://www.businesswire.com/news/home/20261117924250/en/CVRX-INVESTORS-Contact-Kirby-McInerney-LLP-About-the-Securities-Fraud-Lawsuit-Filed-on-Behalf-of-CVRx-Inc.-Shareholders
Kirby McInerney LLP is reminding investors of CVRx, Inc. (NASDAQ: CVRX) to contact them regarding a securities fraud class action lawsuit. The lawsuit alleges that CVRx engaged in illegal sales practices, including improper marketing, kickbacks, and false information to government health insurance programs, which artificially inflated its revenues. This misconduct was revealed when CVRx disclosed a civil investigative demand from the U.S. Department of Justice, causing a significant drop in its stock price.

CVRx to Participate at the Piper Sandler 38th Annual Healthcare Conference

https://www.globenewswire.com/news-release/2026/11/17/3405170/0/en/cvrx-to-participate-at-the-piper-sandler-38th-annual-healthcare-conference.html
CVRx, Inc. (NASDAQ: CVRX) announced its management team will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026, at 3:00 p.m. ET. A live audio webcast of the event will be available on the company's investor relations page. CVRx is a medical device company focused on neuromodulation solutions for cardiovascular diseases, with its Barostim™ technology approved by the FDA for heart failure.

CVRX Shareholder Alert: January 8, 2027 Lead Plaintiff Deadline in CVRx, Inc. Securities Class Action - Contact Levi & Korsinsky

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/cvrx-shareholder-alert-january-8-2027-lead-plaintiff-deadline-in-1252048
Levi & Korsinsky, LLP has filed a securities class action lawsuit against CVRx, Inc. (NASDAQ: CVRX) on behalf of investors who purchased securities between July 25, 2023, and August 6, 2026. The lawsuit alleges that CVRx engaged in illegal sales practices, including improper marketing of Barostim, kickbacks, and providing false information to government health insurance programs, leading to unsustainable revenues. Investors who suffered losses are encouraged to contact Levi & Korsinsky by the lead plaintiff deadline of January 8, 2027.

Levi & Korsinsky Reminds CVRx, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of January 8, 2027 - CVRX

https://www.globenewswire.com/news-release/2026/11/16/3403764/3080/en/levi-korsinsky-reminds-cvrx-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-january-8-2027-cvrx.html
Levi & Korsinsky, LLP reminds investors of CVRx, Inc. (Nasdaq: CVRX) about a pending securities class action lawsuit against two chief executives and a chief financial officer. The lawsuit alleges that these officers, who certified SEC filings, controlled disclosures that omitted Barostim kickback and False Claims Act risks, leading to a 60% stock decline after August 6, 2026 disclosures. Shareholders who purchased CVRx common stock between July 25, 2023, and August 6, 2026, have until January 8, 2027, to apply for lead plaintiff status.
Advertisement

New Analyst Forecast: $CVRX Given $2 Price Target

https://www.quiverquant.com/news/New+Analyst+Forecast%3A+%24CVRX+Given+%242+Price+Target
Cantor Fitzgerald analyst Sarah James has set a $2.0 price target for CVRX (CVRX). This new forecast is consistent with the median target from three analysts over the last six months. The article also details recent insider trading activity, showing both purchases and sales, and significant hedge fund movements in CVRX stock.

SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against CVRx, Inc. (NASDAQ: CVRX) — Investors Who Suffered Losses Are Encouraged to Contact the Firm

https://www.lincolnjournal.com/online_features/press_releases/shareholder-alert-bronstein-gewirtz-grossman-llc-announces-class-action-against-cvrx-inc-nasdaq-cvrx-investors/article_b807d72b-d90d-57eb-87ec-d25f2d4c76fa.html
Bronstein Gewirtz & Grossman, LLC has announced a class action lawsuit against CVRx, Inc. (NASDAQ: CVRX), encouraging investors who suffered losses between July 26, 2021, and August 6, 2024, to contact the firm. The lawsuit alleges that CVRx made false and misleading statements, failing to disclose illegal and unsustainable sales practices, including improper marketing of Barostim and offering kickbacks. This alleged misconduct led to unsustainable revenues and increased legal risks for the company.

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx, Inc. (CVRX) Investors with Substantial Losses to Contact Firm, Securities Class Action Filed

https://www.prnewswire.com/news-releases/hagens-berman-national-securities-law-firm-encourages-cvrx-inc-cvrx-investors-with-substantial-losses-to-contact-firm-securities-class-action-filed-302939051.html
Hagens Berman, a national shareholder rights litigation firm, has filed a class action lawsuit against CVRx, Inc. (NASDAQ: CVRX) following disclosures of a U.S. Department of Justice Civil Investigative Demand, severe cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company's Chief Revenue Officer. Investors who suffered substantial losses are encouraged to contact the firm to evaluate their legal rights and recovery options, with the lead plaintiff deadline set for January 8, 2026. The lawsuit focuses on alleged misleading statements regarding the company's sales force and Medicare Advantage reimbursement rates for its Barostim device.

SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against CVRx, Inc. (NASDAQ: CVRX) -- Investors Who Suffered Losses Are Encouraged to Contact the Firm.

https://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-class-action-against-cvrx-inc-nasdaq-cvrx--investors-who-suffered-losses-are-encouraged-to-contact-the-firm-302936097.html
Bronstein Gewirtz & Grossman, LLC has announced a class action lawsuit against CVRx, Inc. (NASDAQ: CVRX) on behalf of investors who purchased securities between July 25, 2023, and August 6, 2026. The lawsuit alleges that CVRx and its employees engaged in illegal and unsustainable sales practices, including improper marketing of Barostim, offering kickbacks, and providing false information to government health insurance programs, which made the Company's revenue statements materially false and misleading. Investors who suffered losses are encouraged to contact the firm by the lead plaintiff deadline of January 8, 2027.

CVRX Class Action Reminder - Robbins LLP Reminds Investors

https://www.globenewswire.com/news-release/2026/11/13/3402361/32719/en/cvrx-class-action-reminder-robbins-llp-reminds-investors-of-the-lead-plaintiff-deadline-in-the-cvrx-inc-class-action-lawsuit.html
Robbins LLP reminds investors of a class action lawsuit filed against CVRx, Inc. (NASDAQ: CVRX) for allegedly misleading investors regarding illegal sales practices, including kickbacks and false claims to government health insurance programs. The lawsuit covers investors who purchased CVRx common stock between July 25, 2023, and August 6, 2026. The stock dropped significantly after CVRx disclosed a civil investigative demand from the U.S. Department of Justice concerning a False Claims Act investigation.
Advertisement

CVRX Investors Have Opportunity to Lead CVRx, Inc. Securities Fraud Lawsuit with SBS Law

https://www.businesswire.com/news/home/20261112342761/en/CVRX-Investors-Have-Opportunity-to-Lead-CVRx-Inc.-Securities-Fraud-Lawsuit-with-SBS-Law
Schall, Brown & Schwartz LLP (SBS) has reminded investors of CVRx, Inc. (NASDAQ: CVRX) about a class action lawsuit alleging securities fraud. The lawsuit claims CVRx engaged in unsustainable sales practices, including paying kickbacks, leading to false and misleading statements during the class period of July 25, 2023, and August 6, 2026. Investors who suffered losses are encouraged to contact SBS by the January 8, 2027 deadline to potentially become lead plaintiff.

CVRX SHAREHOLDER NOTICE: CVRx, Inc. Investors with Substantial Losses Have Opportunity to Lead the CVRx Class Action Lawsuit

https://www.globenewswire.com/news-release/2026/11/12/3402292/0/en/cvrx-shareholder-notice-cvrx-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-cvrx-class-action-lawsuit.html
Hagens Berman has filed a class action lawsuit against CVRx, Inc. (NASDAQ: CVRX), alerting investors to significant losses following disclosures of a U.S. Department of Justice Civil Investigative Demand, severe cuts to revenue guidance, commercial sales force disruption, and the termination of the company's Chief Revenue Officer. The lawsuit focuses on whether CVRx misled investors about its sales force transformation and Medicare Advantage reimbursement rates, which led to a 60% stock price drop. Investors who suffered substantial losses are encouraged to submit their information to evaluate legal rights and recovery options.

CVRx, Inc. (CVRX) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/CVRX/
This article provides a comprehensive overview of CVRx, Inc. (CVRX), a medical device company specializing in neuromodulation solutions for cardiovascular diseases. It includes detailed stock information such as real-time price, historical data, key performance indicators, and analyst ratings. The company overview highlights its Barostim product and its market presence in the US, Germany, and internationally.

CVRx enables first Barostim implant access at Vassar Brother Medical Center

https://tradersunion.com/news/companies/show/4220018-cvrx-barostim-partnership/
CVRx has partnered with Vassar Brother Medical Center to enable the facility's first Barostim implant procedure, providing patients with access to a new device therapy. This collaboration is a significant operational milestone for both CVRx and the medical center, expanding treatment options for specific patient populations. CVRx has also supported similar initiatives and trials earlier this year to further deploy its Barostim technology in clinical settings.

CVRx, Inc. (CVRX) Securities Class Action

https://www.hbsslaw.com/cases/cvrx-inc-cvrx-securities-class-action
Hagens Berman is investigating a securities class action against CVRx, Inc. (CVRX) following a significant 59% stock drop on August 7, 2026. The investigation stems from revelations of a DOJ Civil Investigative Demand concerning alleged false claims and kickbacks, alongside deteriorating sales force performance and a collapse in Medicare Advantage payer approvals. The firm is seeking investors with substantial losses and is also interested in information from former CVRx employees.
Advertisement

CVRX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in CVRx, Inc. Securities Lawsuit - Contact SueWallSt

https://www.prnewswire.com/news-releases/cvrx-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-cvrx-inc-securities-lawsuit---contact-suewallst-302937459.html
SueWallSt is notifying institutional investors in CVRx, Inc. (Nasdaq: CVRX) that a class action lawsuit has been filed, alleging that the company's sales growth was partly driven by improper marketing, kickbacks, and false claims to government health programs. Shareholders who purchased securities between July 25, 2023, and August 6, 2026, and experienced losses may seek to become lead plaintiff by the January 8, 2027 deadline. The lawsuit comes after CVRx disclosed a Department of Justice civil investigative demand and lowered its outlook, leading to a significant stock decline.

Securities Fraud Class Action Filed Against CVRx, Inc.: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline

https://www.mycarrollcountynews.com/online_features/press_releases/article_d99d54e0-6d84-5b67-9e8e-0265eb911c69.html
A securities fraud class action has been filed against CVRx, Inc. (NASDAQ: CVRX) alleging that the company engaged in illegal and unsustainable sales practices, including improper marketing, kickbacks, and false information to government health insurance programs, in violation of the False Claims Act and Anti-Kickback Statute. Investors who purchased CVRx securities between July 25, 2023, and August 6, 2026, and suffered losses, may be eligible to join the lawsuit. Glancy Prongay Wolke & Rotter LLP is representing the investors, and the lead plaintiff deadline is January 8, 2027.

CRVX Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Arbor Realty Trust, Inc.

https://www.morningstar.com/news/pr-newswire/20261111la94920/crvx-shareholder-notice-shareholder-rights-law-firm-robbins-llp-reminds-investors-of-the-class-action-lawsuit-against-arbor-realty-trust-inc
Robbins LLP is reminding investors of a class action lawsuit filed against CVRx, Inc. (CRVX) on behalf of shareholders who purchased stock between July 25, 2023, and August 6, 2026. The lawsuit alleges CVRx misled investors about illegal sales practices, including improper marketing and kickbacks, which exposed the company to False Claims Act and Anti-Kickback Statute liability. CVRx's stock dropped 60% after it disclosed a civil investigative demand from the U.S. Department of Justice related to these allegations.

CVRX: Execution across all nine regions is the controllable path back to double-digit growth

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4573515:0-cvrx-execution-across-all-nine-regions-is-the-controllable-path-back-to-double-digit-growth/
CVRx, Inc. (CVRX) faces challenges including a low Medicare Advantage payer approval rate, health-system payment concerns, and specialist turnover, which are hindering adoption. Management believes that strong execution across all nine regions, coupled with investments in clinical evidence and reimbursement appeals, is the key to returning to double-digit growth. This analysis is based on the company's participation in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum.

CVRX Shareholder Alert: January 8, 2027 Lead Plaintiff Deadline in CVRx, Inc. Securities Class Action - Contact Levi & Korsinsky

https://www.prnewswire.com/news-releases/cvrx-shareholder-alert-january-8-2027-lead-plaintiff-deadline-in-cvrx-inc-securities-class-action---contact-levi--korsinsky-302936650.html
Levi & Korsinsky, LLP has issued a shareholder alert regarding a securities class action against CVRx, Inc. (Nasdaq: CVRX), naming former Chief Revenue Officer Robert John as a defendant. The lawsuit alleges misrepresentations about sales force stability and improper Barostim sales practices, leading to a significant stock price decline. Investors who purchased CVRx common stock between July 25, 2023, and August 6, 2026, have until January 8, 2027, to seek appointment as lead plaintiff.
Advertisement

ROSEN, LEADING INVESTOR COUNSEL, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRX

https://www.globenewswire.com/news-release/2026/11/11/3400415/673/en/rosen-leading-investor-counsel-encourages-cvrx-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-cvrx.html
Rosen Law Firm is encouraging investors of CVRx, Inc. (NASDAQ: CVRX) to secure legal counsel before the January 8, 2027, deadline for a securities class action lawsuit. The lawsuit alleges that CVRx made false and misleading statements regarding its revenue growth, sales practices, regulatory compliance, and sales-force productivity, leading to investor damages. Investors who purchased CVRx common stock between July 25, 2023, and August 6, 2026, may be entitled to compensation.

ROSEN, LEADING INVESTOR COUNSEL, Encourages CVRx, Inc.

https://www.globenewswire.com/news-release/2026/11/11/3400415/0/en/rosen-leading-investor-counsel-encourages-cvrx-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-cvrx.html
Rosen Law Firm is encouraging CVRx, Inc. investors to join a class action lawsuit before the January 8, 2027, deadline. The lawsuit alleges that CVRx made false and misleading statements regarding its revenue growth, sales practices, regulatory compliance, reimbursement strategy, and sales-force productivity, including improper marketing and kickbacks. Investors who purchased CVRx common stock between July 25, 2023, and August 6, 2026, may be entitled to compensation.

Securities Fraud Lawsuit Filed Against CVRx, Inc.: The Law Offices of Frank R. Cruz Outlines Lead Plaintiff Deadline

https://www.mycarrollcountynews.com/online_features/press_releases/article_d8cdcf0b-1432-58ae-890a-992d6b77e518.html
A securities class action lawsuit has been filed against CVRx, Inc. on behalf of investors who purchased securities between July 25, 2023, and August 6, 2026. The lawsuit alleges that CVRx and its employees engaged in illegal and unsustainable sales practices, including improper marketing, kickbacks, and false information to government health insurance programs, which artificially inflated revenue. Investors have until January 8, 2027, to file for lead plaintiff status.

Securities Class Action Filed Against CVRx, Inc. – CVRX Investors Encouraged to Contact Kirby McInerney LLP

https://www.businesswire.com/news/home/20261110777309/en/Securities-Class-Action-Filed-Against-CVRx-Inc.-CVRX-Investors-Encouraged-to-Contact-Kirby-McInerney-LLP
Kirby McInerney LLP has filed a class action lawsuit against CVRx, Inc. on behalf of investors who purchased securities between July 25, 2023, and August 6, 2026. The lawsuit alleges that CVRx engaged in illegal sales practices, including improper marketing and kickbacks, leading to unsustainable revenues. This follows CVRx's disclosure of a civil investigative demand from the U.S. Department of Justice regarding false claims to government health insurance programs, which caused a significant drop in its stock price.

CVRX INVESTOR ALERT: Securities Class Action Filed, Hagens Berman Urges CVRx, Inc. Investors with Substantial Losses to Contact Firm Ahead of January 8, 2027 Lead Plaintiff Deadline

https://www.prnewswire.com/news-releases/cvrx-investor-alert-securities-class-action-filed-hagens-berman-urges-cvrx-inc-investors-with-substantial-losses-to-contact-firm-ahead-of-january-8-2027-lead-plaintiff-deadline-302935157.html
Hagens Berman has filed a securities class action lawsuit against CVRx, Inc. (NASDAQ: CVRX) following disclosures of a U.S. Department of Justice Civil Investigative Demand, significant cuts to revenue guidance, and sales force disruption. Investors who suffered substantial losses between July 25, 2023, and August 6, 2026, are encouraged to contact the firm before the January 8, 2027, lead plaintiff deadline to evaluate their legal rights and recovery options. The lawsuit alleges that CVRx may have misled investors regarding its sales force and Medicare Advantage reimbursement rates.
Advertisement

CVRx faces class action after DOJ probe, revenue cuts, and sales issues hit stock by 60%.

https://pluang.com/en/news-feed/peringatan-investor-cvrx-gugatan-class-action-doj-cid-masalah-penjualan
CVRx, Inc. is facing a class action lawsuit following a U.S. Department of Justice investigation into potential false claims and kickbacks related to its heart failure device Barostim. The company's stock plummeted 60% after it cut its 2026 revenue guidance and disclosed issues with its sales force and Medicare Advantage approvals. The lawsuit alleges that CVRx misled investors, and individuals who suffered losses are encouraged to submit claims.

Class action lawsuit filed against CVRx after DOJ probe and revenue cuts cause 60% stock plunge

https://pluang.com/en/news-feed/cvrx-investor-gugatan-kelas-penyelidikan-doj-pemotongan-pendapatan
Hagens Berman has filed a class action lawsuit against CVRx, Inc. following a U.S. Department of Justice investigation, significant revenue guidance cuts, and sales force issues. The lawsuit comes after CVRx's stock plummeted 60% due to revelations that the DOJ is probing improper marketing of its Barostim device or false claims, alongside the sudden termination of its Chief Revenue Officer. Investors who experienced losses between July 2023 and August 2026 are urged to explore their legal options.

Lawsuit filed against CVRx over alleged false sales and kickback practices, causing stock to plunge 60%.

https://pluang.com/en/news-feed/berman-tabacco-ajukan-gugatan-kelas-terhadap-cvrx
Berman Tabacco has filed a class action lawsuit against CVRx and its officers, alleging they misled investors about revenue growth, sales practices, and regulatory compliance. This lawsuit follows CVRx's disclosure of a DOJ investigation into improper marketing and kickbacks related to its Barostim device, coupled with a reduced 2026 revenue forecast. The revelations caused CVRx's stock to drop 60%, and investors have until January 8, 2027, to file as Lead Plaintiff.

Berman Tabacco Files Securities Class Action Lawsuit Against CVRx, Inc. (CVRX)

https://www.globenewswire.com/news-release/2026/11/09/3399062/0/en/berman-tabacco-files-securities-class-action-lawsuit-against-cvrx-inc-cvrx.html
Berman Tabacco has filed a class action lawsuit against CVRx, Inc. and its officers, alleging that the medical device company made false and misleading statements about its revenue growth, sales practices, and regulatory compliance. The lawsuit claims that CVRx engaged in improper marketing, kickbacks, and provided false information to government health insurance programs, exposing the company to liability under the False Claims Act and Anti-Kickback Statute. These allegations emerged after CVRx disclosed a civil investigative demand from the U.S. Department of Justice and cut its 2026 revenue outlook, leading to a significant drop in its stock price.

CVRx (CVRX) Q3 2026 Earnings Call: Forecast Cut Due to Reimbursement Delays

https://www.tradingkey.com/es/news/transcripts/262294036-
CVRx reported a 6.1% year-over-year revenue decline to $13.8 million in Q3 2026, widening its net loss to $14.2 million. The company has reduced its full-year revenue guidance to $56-$57 million, citing ongoing Medicare Advantage reimbursement delays, specialist turnover, and inconsistent commercial execution. Despite these challenges, CVRx is implementing cost reduction measures and focusing on improving sales execution, with a cash position of $58.7 million providing at least 18 months of liquidity.
Advertisement

Earnings Update: CVRx, Inc. (NASDAQ:CVRX) Just Reported And Analysts Are Trimming Their Forecasts

https://simplywall.st/stocks/us/healthcare/nasdaq-cvrx/cvrx/news/earnings-update-cvrx-inc-nasdaqcvrx-just-reported-and-analys
CVRx, Inc. (NASDAQ:CVRX) shares plunged 38% after its latest quarterly results, with revenues meeting forecasts but losses exceeding predictions by 4.2%. Analysts have since trimmed their 2027 revenue forecasts slightly, now expecting US$60.5m, but improved their loss per share estimates to US$1.85. The consensus price target for CVRx also fell 31% to US$4.08, reflecting a more pessimistic outlook despite the reduction in loss forecasts.

Lake Street maintains CVRx at Hold, lowers price target to $1.50 from $3.50

https://www.tradingview.com/news/tradingview:e5f68fd801593:0-lake-street-maintains-cvrx-at-hold-lowers-price-target-to-1-50-from-3-50/
Lake Street has reiterated its "Hold" rating for CVRx, but significantly reduced its price target from $3.50 to $1.50, a 57.1% decrease. This new target implies a potential upside of 72.7% from the stock's closing price of $0.87 on November 6. Investors can find more detailed price target data and analyst recommendations for CVRx on the TradingView platform.

Canaccord Downgrades CVRx Inc (CVRX) to Hold

https://www.streetinsider.com/Analyst+Comments/Canaccord+Downgrades+CVRx+Inc+%28CVRX%29+to+Hold/27303893.html
Canaccord analyst William Plovanic downgraded CVRx Inc (NASDAQ: CVRX) from Buy to Hold, reducing the price target from $5.00 to $2.00. This downgrade follows disappointing Q3 results, a cut in FY26 guidance, and persistent headwinds primarily outside the company's control, such as payer denials and a shortage of specialists. The analyst also cited balance sheet concerns and continued dilution risk as factors for the revised rating.

CVRx, Inc. downgraded by Canaccord Genuity with a new price target

https://www.quantisnow.com/insight/cvrx-inc-downgraded-by-canaccord-genuity-with-a-new-price-6778038
Canaccord Genuity downgraded CVRx, Inc. (NASDAQ: CVRX) from "Buy" to "Hold" and set a new price target of $2.00. Historically, CVRX stock has shown mixed performance following headlines, closing higher 12 times and lower 13 times across 25 sessions, with a median move of 3.7%. This particular downgrade led to a significant -40.9% change for CVRX on November 6, 2026.

William Blair downgrades CVRx stock rating on reimbursement headwinds

https://www.investing.com/news/analyst-ratings/william-blair-downgrades-cvrx-stock-rating-on-reimbursement-headwinds-93CH-5006531
William Blair has downgraded CVRx Inc (NASDAQ:CVRX) to Market Perform from Outperform due to significant reimbursement headwinds, including worsening denials from its largest Medicare Advantage payer and struggles in sales productivity. The company also reported third-quarter 2026 revenue below expectations and cut its full-year guidance, with the stock plunging 85% over the past year. Despite efforts to secure new coverage policies and advance clinical programs, William Blair anticipates these challenges will persist into 2027.
Advertisement

CVRx earnings missed by $0.02, revenue fell short of estimates

https://www.investing.com/news/earnings/cvrx-earnings-missed-by-002-revenue-fell-short-of-estimates-5005638
CVRx reported a third-quarter EPS of $-0.52, missing analyst estimates by $0.02, and revenue of $13.8M, falling short of the consensus estimate of $13.94M. The company also issued Q4 2026 revenue guidance of $11.70M-$12.70M and full-year 2026 revenue guidance of $56.00M-$57.00M, both below analyst expectations. CVRx's stock price has declined significantly over the past 3 and 12 months, with its financial health rated as "fair performance" by InvestingPro.

Quarterly loss widens to $14.2M at CVRx (CVRX) as revenue falls.

https://www.stocktitan.net/sec-filings/CVRX/8-k-cv-rx-inc-reports-material-event-6f9333fc96c3.html
CVRx, Inc. reported a Q3 2026 revenue of $13.8 million, a 6% decrease year-over-year, largely due to lower sales force productivity and challenges with a major payer. The company's net loss widened to $14.2 million, or $0.52 per share, compared to $12.9 million, or $0.49 per share, in Q3 2025. CVRx projects Q4 2026 revenue between $11.7 million and $12.7 million and has adjusted its full-year 2026 revenue guidance downwards.

CVRx, Inc. (CVRX) Misses Q3 EPS by 2c, Lowers FY2026 Revenue Guidance

https://www.streetinsider.com/Earnings/CVRx%2C+Inc.+%28CVRX%29+Misses+Q3+EPS+by+2c%2C+Lowers+FY2026+Revenue+Guidance/27299894.html
CVRx, Inc. (CVRX) reported a Q3 EPS of ($0.52), missing analyst estimates by $0.02, and revenue of $13.8 million, slightly below the consensus. The company also lowered its FY2026 revenue guidance to $56-57 million, falling short of previous expectations. CVRx projects Q4 2026 revenue to be between $11.7-12.7 million.

CVRx Reports Third Quarter 2026 Financial and Operating Results

https://www.globenewswire.com/news-release/2026/11/05/3397074/0/en/cvrx-reports-third-quarter-2026-financial-and-operating-results.html
CVRx, Inc. announced its Q3 2026 financial and operating results, reporting $13.8 million in total revenue, a 6% decrease year-over-year, and a net loss of $14.2 million. Despite the revenue decline, the company highlighted increased Medicare Advantage coverage for its Barostim device and positive clinical evidence presented at the HFSA Annual Scientific Meeting. CVRx also revised its full-year 2026 revenue guidance downwards and appointed John Landry as its new Chief Financial Officer.

Hagens Berman probes CVRx after 59% stock drop and CRO exit

https://scanx.trade/stock-market-news/companies/block-leviton-probes-cvrx-inc-for-fraud-after-guidance-cut/47915923
Law firm Hagens Berman has initiated an investigation into CVRx, Inc. for potential securities fraud, following a 59% stock decline and the termination of its Chief Revenue Officer. The probe, which comes after an initial investigation by Block & Leviton, focuses on whether CVRx misled investors regarding its sales force health and declining Medicare Advantage reimbursement rates, which plummeted from 80% to 25% approval within 30 days. These issues, coupled with a Department of Justice inquiry into false claims and kickbacks, led to a significant cut in the company's full-year revenue guidance.
Advertisement

CVRx to Participate in Upcoming Investor Conferences

https://www.globenewswire.com/news-release/2026/11/02/3393705/0/en/cvrx-to-participate-in-upcoming-investor-conferences.html
CVRx, Inc. (NASDAQ: CVRX), a medical device company specializing in neuromodulation solutions for cardiovascular diseases, announced its participation in two investor conferences in November 2026. The management team will attend the Canaccord Genuity Medtech, Diagnostics & Digital Health Services Forum on November 11 and the Jefferies Global Healthcare Conference on November 19, with webcasts available for both events. CVRx focuses on its Barostim™ device, approved by the FDA for heart failure patients.

Earnings Preview: CVRx Inc to Report Financial Results Post-market on November 05

https://www.moomoo.com/news/post/1003076020/earnings-preview-cvrx-inc-to-report-financial-results-post-market
CVRx Inc. (NASDAQ:CVRX) is scheduled to release its next quarterly earnings report after the market closes on November 5. Analysts are expecting the medical device company to post earnings of ($0.38) per share for the current quarter. Investors will be watching for the actual results compared to these expectations.

CVRx Inc (CVRX) Cash Flow Statement

https://www.moomoo.com/stock/CVRX-US/financials-cash-flow?chain_id=Name1K9-3FXPhg.1kuvu40&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2FIRDM-US%22%7D
This article provides the cash flow statement for CVRx Inc (CVRX). It details the company's financial movements over a specific period, covering operational, investing, and financing activities. The complete cash flow statement is presented for review.

CVRX Q3'26 Earnings: revenue estimate is 13.93M USD

https://www.tradingview.com/news/tradingview:0a45ba95adb1c:0-cvrx-q3-26-earnings-revenue-estimate-is-13-93m-usd/
CVRx, Inc. (CVRX) is scheduled to release its Q3'26 financial results on November 5, after market close, specifically at 4:05 PM ET (9:05 PM UTC). Analysts estimate revenue for the quarter to be $13.93 million, with an anticipated EPS of ($0.50) USD. The article also provides a table of historical and estimated revenue and EPS figures.

CVRx, Inc. Estimates – NASDAQ:CVRX

https://www.tradingview.com/symbols/NASDAQ-CVRX/financials-estimates/
This article from TradingView provides an overview of CVRx, Inc. (NASDAQ:CVRX) financial estimates. It highlights access to reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics. Users can compare actual results with average, high, and low estimates, and visualize trends over time.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement